X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs DR. REDDYS LAB - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. DR. REDDYS LAB WOCKHARDT LTD./
DR. REDDYS LAB
 
P/E (TTM) x 16.7 27.3 61.2% View Chart
P/BV x 1.7 2.8 60.6% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 WOCKHARDT LTD.   DR. REDDYS LAB
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-16
DR. REDDYS LAB
Mar-16
WOCKHARDT LTD./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2,0004,383 45.6%   
Low Rs7062,750 25.7%   
Sales per share (Unadj.) Rs403.7920.1 43.9%  
Earnings per share (Unadj.) Rs29.5126.1 23.4%  
Cash flow per share (Unadj.) Rs42.4183.0 23.2%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs323.4685.8 47.2%  
Shares outstanding (eoy) m110.51170.61 64.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.9 86.5%   
Avg P/E ratio x45.928.3 162.3%  
P/CF ratio (eoy) x31.919.5 163.8%  
Price / Book Value ratio x4.25.2 80.4%  
Dividend payout %015.9 0.0%   
Avg Mkt Cap Rs m149,509608,481 24.6%   
No. of employees `0007.421.7 34.0%   
Total wages/salary Rs m9,44331,874 29.6%   
Avg. sales/employee Rs Th6,048.67,244.4 83.5%   
Avg. wages/employee Rs Th1,280.21,470.9 87.0%   
Avg. net profit/employee Rs Th441.5992.8 44.5%   
INCOME DATA
Net Sales Rs m44,614156,978 28.4%  
Other income Rs m9702,693 36.0%   
Total revenues Rs m45,584159,671 28.5%   
Gross profit Rs m5,03834,587 14.6%  
Depreciation Rs m1,4269,705 14.7%   
Interest Rs m1,012824 122.8%   
Profit before tax Rs m3,57026,751 13.3%   
Minority Interest Rs m-650-   
Prior Period Items Rs m60-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2555,237 4.9%   
Profit after tax Rs m3,25721,514 15.1%  
Gross profit margin %11.322.0 51.3%  
Effective tax rate %7.119.6 36.5%   
Net profit margin %7.313.7 53.3%  
BALANCE SHEET DATA
Current assets Rs m39,906118,201 33.8%   
Current liabilities Rs m18,42368,368 26.9%   
Net working cap to sales %48.231.7 151.7%  
Current ratio x2.21.7 125.3%  
Inventory Days Days9060 150.3%  
Debtors Days Days9897 101.4%  
Net fixed assets Rs m35,83272,265 49.6%   
Share capital Rs m553853 64.8%   
"Free" reserves Rs m30,370111,548 27.2%   
Net worth Rs m35,739117,009 30.5%   
Long term debt Rs m16,54210,690 154.7%   
Total assets Rs m79,522200,104 39.7%  
Interest coverage x4.533.5 13.5%   
Debt to equity ratio x0.50.1 506.6%  
Sales to assets ratio x0.60.8 71.5%   
Return on assets %5.411.2 48.1%  
Return on equity %9.118.4 49.6%  
Return on capital %8.721.6 40.1%  
Exports to sales %11.646.3 25.1%   
Imports to sales %4.59.0 49.8%   
Exports (fob) Rs m5,17772,618 7.1%   
Imports (cif) Rs m1,99014,050 14.2%   
Fx inflow Rs m7,58975,405 10.1%   
Fx outflow Rs m2,87827,115 10.6%   
Net fx Rs m4,71148,290 9.8%   
CASH FLOW
From Operations Rs m71640,476 1.8%  
From Investments Rs m-8,182-19,421 42.1%  
From Financial Activity Rs m2,543-17,009 -14.9%  
Net Cashflow Rs m-4,9234,046 -121.7%  

Share Holding

Indian Promoters % 74.5 25.5 292.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 5.4 42.6%  
FIIs % 7.7 35.3 21.8%  
ADR/GDR % 0.1 18.5 0.5%  
Free float % 15.4 15.3 100.7%  
Shareholders   67,757 75,885 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Aug 18, 2017 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - DISHMAN PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS